Mundipharma

NORDIC LAUNCH OF THE K-HALER

At W we have in-depth knowledge within the asthma therapy area. Therefore, Mundipharma asked us to support the launch of the K-haler.

Our Challenge

Mundipharma has a portfolio of medicines within diabetes, respiratory, oncology, pain and biosimilars. The k-haler is a breath-triggered inhaler, that automatically releases a dose of medication as the asthma patient breathes in through the mouthpiece. W was asked to support the launch of the k-haler in the Nordics by developing a communication platform campaign to communicate the key benefits of the k-haler to Healthcare Professionals (HCP).

The Solution

Drawing from our in-depth knowledge within the asthma therapy area, the team at W developed a sales story flow and key selling messages to communicate the key benefits of the k-haler. A complex story with complex lung deposition data was translated to an understandable and compelling flow, targeting respiratory specialists treating asthma patients in a hospital setting.

Final Result

After a process of content development and iteration, the k-haler sales presentation was developed as an iPad sales presentation with speaker notes. A tool enabling the Mundipharma sales team to have an interactive discussion with HCPs on the added value of k-haler compared to other breath-actuated inhalers for the management of asthma.

Today it's important to be present, be relevant, and add value.
Nick Besbeas
Global CMO, LinkedIn

Cases

Related work

Check out more cases in the same service.

Newsletter

Get news and inspiration from W straight to your inbox! Sign up for Whispers, our quarterly newsletter.